Kim Jong Wook, Oh Mi Mi
Department of Urology, Korea University Guro Hospital, Seoul, Korea.
Korean J Pediatr. 2013 Apr;56(4):145-50. doi: 10.3345/kjp.2013.56.4.145. Epub 2013 Apr 22.
Endoscopic treatment is a minimally invasive treatment for managing patients with vesicoureteral reflux (VUR). Although several bulking agents have been used for endoscopic treatment, dextranomer/hyaluronic acid is the only bulking agent currently approved by the U.S. Food and Drug Administration for treating VUR. Endoscopic treatment of VUR has gained great popularity owing to several obvious benefits, including short operative time, short hospital stay, minimal invasiveness, high efficacy, low complication rate, and reduced cost. Initially, the success rates of endoscopic treatment have been lower than that of open antireflux surgery. However, because injection techniques have been developed, a recent study showed higher success rates of endoscopic treatment than open surgery in the treatment of patients with intermediate- and high-grade VUR. Despite the controversy surrounding its effectiveness, endoscopic treatment is considered a valuable treatment option and viable alternative to long-term antibiotic prophylaxis.
内镜治疗是一种用于管理膀胱输尿管反流（VUR）患者的微创治疗方法。尽管几种填充剂已用于内镜治疗，但葡聚糖omer/透明质酸是目前美国食品药品监督管理局批准用于治疗VUR的唯一填充剂。由于具有手术时间短、住院时间短、微创、疗效高、并发症发生率低和成本降低等诸多明显优点，VUR的内镜治疗广受欢迎。最初，内镜治疗的成功率低于开放抗反流手术。然而，由于注射技术的发展，最近一项研究表明，在治疗中、重度VUR患者时，内镜治疗的成功率高于开放手术。尽管围绕其有效性存在争议，但内镜治疗被认为是一种有价值的治疗选择，也是长期抗生素预防的可行替代方案。
